Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 8/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 2/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 2/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 2/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 1/20 | 1.00 |
| ▸ | GRIK3 | Q13003 | 1/20 | 1.00 |
| ▸ | GRIK4 | Q16099 | 1/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 1/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974818 | 1.00 | GRIN1 (1.00) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3858628 | 1.00 | GRIN1 (1.00) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL30076660 | 1.00 | GRIN1 (1.00) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL29651441 | 0.99 | GRIN1 (0.98) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL2030014 | 0.99 | GRIN1 (0.98) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL2030010 | 0.99 | GRIN1 (0.98) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5974251 | 0.88 | GRIN1 (0.78) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5974390 | 0.86 | GRIN1 (0.75) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5973750 | 0.85 | GRIN1 (0.74) | GRIN1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5973785 | 0.85 | GRIN1 (1.00) | GRIN1GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060293282-A1 | Substituted aminoalkanephosphonic acids | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | claimed |
| EP-1501518-A2 | SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS FOR THE TREATMENT OF NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDERS, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDERS | Novartis AG (CH) | 2005-02-02 | — | — | EP | claimed |
| WO-2004098603-A1 | USE OF SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS IN THE TREATMENT OF MULTIPLE SCLEROSIS | NOVARTIS AG (CH) | 2004-11-18 | — | — | WO | claimed |
| EP-0853617-B1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 2004-03-03 | — | — | EP | claimed |
| WO-2003092701-A2 | SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS FOR THE TREATMENT OF NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDERS, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDERS | NOVARTIS AG (CH) | 2003-11-13 | — | — | WO | claimed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | claimed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | claimed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| JP-2009137995-A | SUBSTITUTED AMINOALKANEPHOSPHONIC ACID FOR TREATING NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDER, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDER | NOVARTIS AG | 2009-06-25 | — | — | JP | disclosed |
| US-20060293282-A1 | Substituted aminoalkanephosphonic acids | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
| CN-1649599-A | Substituted aminoalkylphosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders | NOVARTIS AG (CH) | 2005-08-03 | — | — | CN | disclosed |
| EP-1501518-A2 | SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS FOR THE TREATMENT OF NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDERS, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDERS | Novartis AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004098603-A1 | USE OF SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS IN THE TREATMENT OF MULTIPLE SCLEROSIS | NOVARTIS AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| EP-0853617-B1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003092701-A2 | SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS FOR THE TREATMENT OF NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDERS, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDERS | NOVARTIS AG (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-6117873-A | CAN BE USED FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS WHICH RESPOND TO BLOCKAGE OF EXCITATORY AMINO ACID RECEPTORS | NOVARTIS AG (CH) | 2000-09-12 | — | — | US | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293282-A1 | Substituted aminoalkanephosphonic acids | AANAT, LPAR6, AADAT | GRIN1 610/4885GRIA1 683/4885GRIA2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.